Immuneering Corp
Immuneering Corporation (Nasdaq: IMRX) is a clinical-stage oncology company developing small-molecule cancer medicines called Deep Cyclic Inhibitors, designed to disrupt tumor signaling pathways on a cyclical basis. Its discovery platform combines bioinformatics analysis of molecular data with proprietary 3D tumor… From the company’s description.
In fiscal 2025, Immuneering Corp reported a net loss of $56.02M. Operations used $45.34M in cash.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Immuneering Corp does
In the company’s own words
Immuneering Corporation (Nasdaq: IMRX) is a clinical-stage oncology company developing small-molecule cancer medicines called Deep Cyclic Inhibitors, designed to disrupt tumor signaling pathways on a cyclical basis. Its discovery platform combines bioinformatics analysis of molecular data with proprietary 3D tumor models to guide drug discovery and development. The lead candidate, atebimetinib, is an oral MEK inhibitor being evaluated in advanced solid tumors, with planned Phase 3 development in combination with chemotherapy for first-line metastatic pancreatic cancer. The pipeline also includes envometinib, a clinical-stage MEK inhibitor whose internal advancement is paused, and earlier research programs targeting other cancer-signaling pathways. Immuneering was founded in 2008 as a translational bioinformatics company and began developing its wholly owned oncology drug pipeline in 2018; it has since ceased its computational biology services business. The company has no approved products for commercial sale and reported no revenue segments. Its website is https://www.immuneering.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- CAMBRIDGE, MA
- Fiscal year end
- December
- CIK
- 1790340
- SIC
- 2834
Financial performance, year by year
Fiscal 2021–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Immuneering Corp — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Immuneering Corp’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Immuneering Corp and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Immuneering Corp's earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Immuneering Corp's last four quarterly filings that the numbers alone won't show?”